Circulating Apoptotic Progenitor Cells in Patients with Congestive Heart Failure by Geft, Dael et al.
Circulating Apoptotic Progenitor Cells in Patients with
Congestive Heart Failure
Dael Geft
., Shmuel Schwartzenberg
., Ori Rogowsky, Ariel Finkelstein, Jacob Ablin, Sofia Maysel-
Auslender, Dov Wexler, Gad Keren, Jacob George*
Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Abstract
Background: Circulating CD34+ endothelial progenitor cells (EPCs) are capable of differentiating into mature endothelial
cells to assist in angiogenesis and vasculogenesis. We sought to quantify the numbers of apoptotic progenitors in patients
with congestive heart failure.
Methods and Results: Peripheral blood mononuclear cells were isolated by Ficoll density-gradient from 58 patients with
various degrees of heart failure and 23 matched controls. Apoptosis in progenitor CD34+ cells was assessed using the
Annexin V-PE/PI detection kit, and FACS analysis was performed with triple staining for CD34, annexin-V and propidium
iodide. The percentage of early and late apoptotic progenitor cells was determined in the subject groups and was
correlated with clinical characteristics. While there was no significant difference in total CD34 positive cells or early
apoptotic progenitors between control subjects and CHF patients (p=0.42) or between severe and mild/moderate CHF
groups (p=0.544), there was an elevated number of late apoptotic progenitors in the severe CHF group compared with the
mild/moderate CHF group (p= 0.03). Late apoptotic progenitors were significantly increased in CHF patients as compared
to matched controls. There was also an inverse correlation between late apoptotic progenitors and ejection fraction
(r=20.252, p=0.028) as well as a positive association with NYHA class (r=0.223, p=0.046).
Conclusion: Severe heart failure patients exhibited higher numbers of late apoptotic progenitors, and this was positively
associated with NYHA class and negatively correlated with ejection fraction. This finding may shed light on the numerous
factors governing the pathophysiology of CHF.
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Introduction
Over the past few decades, researchers as well as clinicians have
made great strides in understanding the pathophysiological
mechanisms of heart failure. Whereas heart failure was once
thought of as a series of symptoms simply due to a poorly
functioning heart, it is now understood to be a syndrome whose
causes are both multifactorial and complex [1]. Several diverse
mechanisms contribute to this syndrome including structural and
functional abnormalities of the heart, vascular disease, biological
and neurohormonal factors, oxidative stress, genetics, environ-
ment and coexisting conditions [1]. Yet, while these advancements
in understanding have indeed led to better treatment of heart
failure, it remains a major cause of morbidity and mortality
worldwide.
More recently, considerable evidence has shown that heart
failure is associated with tissue ischemia and endothelial
dysfunction, as assessed by impaired flow-mediated dilatation, as
well as increases in specific plasma markers such as von
Willebrand factor and soluble thrombomodulin [2–5]. A newer
method to identify endothelial damage and dysfunction is the
quantification of circulating endothelial cells (CECs) and endo-
thelial progenitor cells (EPCs) in the peripheral circulation. CECs
are mature endothelial cells that have detached from the intimal
monolayer of blood vessels in response to endothelial injury [6],
whereas EPCs are immature, bone-marrow derived cells with the
capacity to transform into mature endothelial cells and promote
postnatal angiogenesis and vasculogenesis [7–9]. EPCs can be
characterized by the expression of surface markers, such as CD34,
CD133 and VEGFR-2 (KDR or Flk-1) in various combinations
[10]. It has, in fact, recently been shown by us that patients with
heart failure have elevated circulating EPCs, which may be an
independent predictor of mortality in CHF [11].
There are small membrane particles, known as endothelial
microparticles, which are associated with endothelial cell damage
and apoptosis. These endothelial microparticles have been shown
to be elevated in conditions such as acute coronary syndrome
(ACS) and myocardial infarction [12–14]. Recently, we identified,
for the first time, a new population of apoptotic progenitor cells
(APCs) which were elevated in patients with ACS [15]. The
apoptotic progenitors can be divided into early, reversible
apoptotic cells and late, irreversible apoptotic cells. In this study,
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patients with heart failure. In so doing, we learned that while CHF
patients did not exhibit higher levels of total or early apoptotic
progenitors than controls, the more severe CHF patients exhibited
elevated numbers of late apoptotic progenitors compared to those
with less severe CHF.
Materials and Methods
Study Subjects
We studied a total of 58 patients (median age 76.5) arbitrarily
with various classes of heart failure according to the New York
Heart Association (NYHA) classification. The control group
comprised of 23 subjects with a similar profile of age (a median
of 74 years, range 42–81), gender, a normal ejection fraction by
echocardiography and no evidence of heart failure. The incidence
of risk factors for atherosclerosis including diabetes, hypertension,
smoking and treated hyperlipidemia did not differ between the
study and control groups. With regard to medication use, study
group patients had significantly increased use of warfarin and
renal failure was more common as compared with controls. In
addition, as seen in Table 1, we subdivided the 58 CHF patients
into two subgroups: 33 patients with mild/moderate CHF (NYHA
class I–II) and 25 patients with advanced CHF (NYHA class III–
IV). There were no significant differences between the demo-
graphic characteristics of these two subgroups.
Of the CHF patients, 43 were male and 15 were female. Of the
controls, 15 were male and 8 were female. Table 1 summarizes
demographic and clinical characteristics of the patient population.
Institutional ethics committee approved the study and informed
consent was obtained from all patients.
Preparation of Blood Samples
Peripheral blood mononuclear cells (PBMNCs) were isolated
from 20 ml of freshly drawn heparinized blood using Isopaque-
Ficoll (Amersham Biosciences, Buckinghamshire, United King-
dom) gradient centrifugation.
Flow Cytometry evaluation of early and late apoptotic
progenitor CD34+ cells
After Ficoll gradient separation, PBMNCs were washed with
phosphate-buffered saline (PBS), and 10
6 cells were stained with
(FITC)-anti-CD34 MAb for 30 minutes at 4uC in 100 microliters
of FACS staining buffer (PBS and 2% fetal calf serum (FCS).
Apoptosis in progenitor CD34+ progenitor cells was assessed using
Southern Biotech ApoScreen Annexin V Apoptosis detection kit
(Annexin V-PE, Propidium Iodide (PI) solution and Annexin V
binding buffer). This assay involves staining peripheral blood
mononuclear cells with Annexin V-PE (a phospholipid-binding
protein binding to disrupted cell membranes) in combination with
propidium iodide (PI, a vital dye binding to DNA penetrating into
apoptotic cells). FACS analysis of CD34+ progenitor cells that are
in early (annexin V+/PI2) or late (annexin V+/PI+) apoptotic
phase was performed.
The percentage of apoptotic CD34+ progenitor cells (out of
total circulating CD34+ progenitor cells) was assessed by staining
peripheral blood mononuclear cells for 3 color FACS analysis
employing (FITC)-anti-CD34 MAb (IQ products), Annexin V-PE
and Propidium Iodide (SouthernBiotech). The cells were then
washed again with PBS and resuspended in 100 microliters of
Annexin V-PE binding buffer and incubated with 5 microliters of
Annexin V-PE for 15 minutes at room temperature. Without
washing, another 200 microliters of binding buffer and 5 micro-
liters of PI solution were added, and 800,000 cells were acquired
by flow cytometry (FACSCalibur, Becton Dickinson) and analyzed
by CellQuest software (BD Bioscience). All analyses and readings
were made by technicians who were blinded to the study
questions.
Determination of Erythropoietin, Thrombomodulin/
CD141 and Antibodies to Oxidized LDL levels
ELISA kits were used to detect levels of Erythropoietin (Stem
Cell Technologies) and Thrombomodulin/CD141 (Diaclone).
Antibody to oxidative LDL levels were detected by ELISA
method with anti-human antibody and solutions created in the
laboratory [19].
Statistical Analysis
All data was summarized and displayed as mean (SD) for the
continuous variables and as number of patients plus the
percentage in each group for categorical variables. The one-way
Kolmogorov-Smirnov test was used to assess the distributions.
Levels of late apoptotic cells could not be converted to normal
distribution, thus we categorized the variables into tertiles.
For all categorical variables the Chi-Square statistics was used
for assessing the statistical significance between the groups of CHF
Table 1. Baseline characteristics CHF and control patients.
Group Controls NYHA I–II NYHA III–IV P
Characteristics n=23 n=33 n=25
Demographic data
Male/Female 15/8 25/8 18/7
Median age (range) 74 (42–81) 73 (48–89) 74 (47–79) ns
Current Smoker 2 (9%) 6 (18%) 4 (16%)
Comorbidities
Hypertension 12 (52%) 21 (63%) 14 (56%) ns
Diabetes Mellitus 12 (52%) 20 (61%) 14 (56%) ns
Hyperlipidemia 16 (65%) 26 (79%) 15 (60%) ns
Drug Treatment
Statin 16 (65%) 27 (82%) 13 (52%) ns
Beta Blocker 6 (26%) 25 (76%) 19 (76%) ,.01
ACEI/ARB 16 (65%) 27 (82%) 19 (76%) ns
Spironolactone 0 23 (70%) 17 (68%) ,.01
Furosemide 0 33 (100%) 25 (100%) ,.001
,.01
Coumadin 0 14 (42%) 10 (40%) ,.01
Measurements
Ejection Fraction*
.40% 13 (39%) 10 (40%)
#40% 20 (61%) 15 (60%)
Creatinine
.1.5 20 (61%) 16 (64%)
#1.5 13 (39%) 9 (36%)
Ischemic vs. Non-Ischemic
D
Ischemic 16 (64%)
Non-ischemic 20 (36%)
*LV ejection fraction was estimated by 2D echocardiography.
DIschemic cardiomyopathy refers to patients with ischemic heart disease (prior
MI, PTCA or CABG) and ejection fraction ,40%.
doi:10.1371/journal.pone.0003238.t001
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samples one way ANOVA test was used. Regression analysis
and analysis of variance for APCs by independent variables was
performed in all cases.
All above analyses were considered significant at p,0.05 (two
tailed). The SPSS 15 statistical package was used to perform all
statistical evaluations (SSPS Inc., Chicago, IL, USA).
Results
We employed a novel assay for determining apoptotic CD34
cells. Progenitor CD34+ cells were initially gated from the side
scatter/CD34 dot plot according to the Milan protocol [20–21].
As can be seen in Figure 1a, the progenitor CD34+ cells can be
outlined and gated using this FACS dot plot. The percentage of
apoptotic CD34+ progenitor cells was then determined by FACS
analysis of Annexin V/PI staining. In apoptotic cells, the
membrane phospholipids phosphatidylserine (PS) is translocated
from the inner to the outer leaflet of the plasma membrane,
thereby exposing PS to the extracellular environment. Annexin V
is a 36 kDa Ca
2+ dependent phospholipid-binding protein that has
a high affinity for PS and binds to cells when PS is exposed to the
external cellular environment, which occurs when membrane
integrity is affected in early phase of apoptosis [16–17]. Propidium
Iodide (PI) is a vital dye binding to DNA, a process implying
disrupted cellular membrane and exposed DNA, compatible with
late, irreversible cell necrosis. Cells that are viable are Annexin V-
PE and PI negative; cells that are in early apoptosis are Annexin
V-PE positive and PI negative (lower right quadrant–figure 1b);
and cells that are in late apoptosis or necrosis are both Annexin V-
PE and PI positive (upper right quadrant–figure 1b) [17–18].
As can be appreciated in Table 1, there were no significant
statistical differences between the demographic characteristics of
the two study groups (mild-moderate CHF and severe CHF) and
the control group which comprised ACS patients not having CHF.
With regard to the number of early apoptotic cells, no statistically
significant difference was found between the age matched controls
vs. CHF groups (once adjusted for age, gender and risk factors) or
between the two CHF groups (mild/moderate vs. severe) (figure 2).
Within the CHF groups, however, there was a positive correlation
between the number of early apoptotic progenitor cells and levels
of hemoglobin (r=0.279, p=0.016) and total CD34+ cells
(r=0.261, p=0.023). With regard to the late apoptotic cells,
there was an elevated number of cells in the severe CHF group
compared to the mild/moderate CHF group (p= 0.013), as
shown in figure 3. Interestingly, there was a positive association
between late apoptotic cells and NYHA class (r=0.223, p=0.046)
as well as a negative correlation between late apoptotic cells and
ejection fraction (r=20.252, p=0.028). There was also a negative
association between hyperlipidemia and total CD34+ progenitors
in the CHF groups. Tables 2 and 3 demonstrate the parameters
tested for correlations and associations. As shown in table 2,
neither erythropoietin (r=0.072; p=0.3), thrombomodulin/
CD141 (r=0.09; p=0.25), nor antibodies to oxidized LDL levels
(r=20.13; p=0.19) correlated with early apoptotic progenitor
cells.
Discussion
Over the past decade, since the isolation of a circulating
angioblast (later referred to as EPC) from adults with the capacity
Figure 1. Representative flow cytometric dot plots: SSC/CD34
scatter (1a) and flow cytometric evaluation of progenitor
CD34+ apoptotic cell percentage (1b). Dots in the lower right
quadrant represent early apoptotic cells (Annexin-V positive and PI
negative) while dots in the upper right quadrant represent late
apoptotic cells (Annexin-V and PI positive).
doi:10.1371/journal.pone.0003238.g001
Figure 2. Early apoptotic progenitor CD34+ cell percentage
(out of total circulating progenitor CD34+ cells) in mild/
moderate and severe CHF groups. P-value is .0.05 after
adjustment for variables.
doi:10.1371/journal.pone.0003238.g002
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ischemia [9,22], much work has been done to further classify
and characterize the role of endothelial progenitor cells. EPCs are
released from the bone marrow in response to endothelial damage
in order to facilitate in angiogenesis and vasculogenesis. Previous
studies have shown elevated numbers of EPCs in ACS [23–25] as
well as in heart failure [11], presumably due to the release of
angiogenic factors and activation of multiple neurohormonal axes
triggered by tissue ischemia [7]. It is also known that all major
cardiovascular risk factors negatively influence these factors [26].
In CHF there is increased oxidative stress due to an imbalance
between reactive oxygen species (including the superoxide anion,
hydrogen peroxide, and the hydroxyl radical) and endogenous
antioxidant defense mechanisms [32]. Oxidative stress may
damage cellular proteins and cause myocyte apoptosis and
necrosis. Markers of oxidative stress that are increased in CHF
include plasma-oxidized low-density lipoproteins, malondialde-
hyde and myeloperoxidase (an index of leukocyte activation),
urinary levels of biopyrrins (oxidative metabolites of bilirubin), and
isoprostane levels in plasma and urine [32].
Endothelial cell (EC) apoptosis is an additional biomarker of
endothelial damage and hemostasis that has more recently been
explored [27]. The number of circulating endothelial micropar-
ticles positively correlates with the severity of coronary endothelial
dysfunction, suggesting a close relationship between coronary
endothelial-dependent vasodilation and EC apoptosis [12]. In
addition, their functional properties such as their procoagulant
activity, involvement in inflammation and direct effect on
endothelial dysfunction play a large role [28]. We have recently
described a novel assay to detect and quantify circulating apoptotic
CD34+ progenitor cells showing that they were elevated in ACS
patients compared with healthy controls [15].
Similar to ACS, CHF is associated with myocardial and
peripheral tissue ischemia. Thus, CHF patients were found to
exhibit endothelial dysfunction that is correlated with disease
severity [29]. Previous studies have demonstrated elevated levels of
EPCs in heart failure patients [11], yet levels of apoptotic EPCs in
these patients have not been determined so far. In our study, we
sought to quantify these apoptotic progenitor cells in patients with
heart failure. In so doing, we divided these apoptotic cells into two
groups: early, reversible apoptotic CD34+ cells and late,
irreversible apoptotic progenitors. The late apoptotic progenitor
cells represent cells whose plasma membrane is no longer intact.
Our results show that, while there was no significant difference in
numbers of early or late apoptotic cells between CHF patients and
healthy controls, there was an elevated number of late apoptotic
progenitors in the more severe CHF patients compared to the less
severe heart failure patients. Furthermore, there was a negative
correlation between late apoptotic progenitors and ejection
fraction as well as a positive association between late apoptotic
CD34 cells and NYHA class.
Several possible mechanisms could be postulated to explain these
findings. Oxidative stress is known to cause endothelial dysfunction,
and, as mentioned previously, CHF is associated with increased
oxidative stress [32]. It has been demonstrated by Dernbach et al
that EPCs are equipped with antioxidative enzyme systems,
allowing for improved survival of cells undergoing severe oxidative
stress [30]. Oxidized LDL has been shown to increase the rate of
EPC senescence/apoptosis [31]. Antibodies to oxidized LDL are
thought to mirror oxidative stress and have been shown to be
increased in patients with CHF [19]. Although it would be plausible
to explain the increase in late apoptotic cells in the more severe
Figure 3. Late apoptotic progenitor CD34+ cell percentage (out
of total circulating progenitor CD34+ cells) in mild/moderate
(NYHA class 1–3) and severe (NYHA class 4) CHF groups. Chi-
square P value of the distribution of tertiles between NYHA 1–3 &
NYHA=4 is 0.038.
doi:10.1371/journal.pone.0003238.g003
Table 2. Correlations between early apoptotic/late apoptotic/total CD34+ EPCs and various parameters.
Parameter Early Apoptotic Cells Late Apoptotic Cells Total CD34+ cells
r p-value r p-value r p-value
Age 0.013 0.460 0.052 0.350 20.123 0.180
Heart failure duration 20.063 0.318 20.018 0.447 20.058 0.332
LVEF 20.107 0.211 20.252 0.028* 20.152 0.127
Creatinine 0.033 0.403 20.027 0.420 20.049 0.357
Erythropoietin 0.072 0.298 0.157 0.123 0.031 0.409
Thrombomodulin 0.093 0.247 0.091 0.251 0.031 0.411
OxLDL antibodies 20.117 0.194 20.037 0.391 0.041 0.380
Hemoglobin 0.279 0.016* 20.027 0.420 0.176 0.092
CD34% of total 0.261 0.023* 0.213 0.053
*Statistically Significant.
doi:10.1371/journal.pone.0003238.t002
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increased oxidative stress, we did not find a statistically significant
correlation between antibodies to oxidized LDL and apoptotic
progenitor cells. Therefore, the relationship of additional indirect
markers of oxidative stress which are known to be increased in CHF
[32] should be further explored in future studies.
Erythropoietin and thrombomodulin have also been shown to play
a role in endothelial function and heart failure. Both these markers,
erythropoietin being a mobilizer of progenitor cells and thrombo-
modulin being associated with endothelial dysfunction, were not
found to correlate with the number of apoptotic CD34 cells.
In view of the interplay between cytokines enhancing progenitor
cell mobilization and those precipitating their apoptosis, our
results support the hypothesis that increasing severity of heart
failure shifts the balance towards enhanced progenitor cell
apoptosis. The lower the ejection fraction, the poorer the forward
flow, which may increase tissue ischemia and therefore endothelial
damage.
It should be mentioned, however, that the relatively small
number of circulating CD34+ cells poses a question as to the true
functional importance of these cells and imposes a difficulty in
determining their accurate number. In addition, our study is
limited by the relatively small sample size.
In conclusion, we found that patients with advanced CHF have
higher levels of late apoptotic progenitors than those with mild/
moderate CHF and that levels of late apoptotic progenitors were
positively associated with NYHA class and had a negative
correlation with ejection fraction. These findings support the
hypothesis that increasing severity of heart failure shifts the
balance towards enhanced progenitor cell apoptosis. Therefore,
apoptotic progenitor cells could be evaluated in future studies as a
potential predictive biomarker in CHF.
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